A recent study titled "Effect of Cannabis and Subproducts on Anthropometric Measures: A Systematic Review and Meta-Analysis" published in the International Journal of Obesity, explored the impact of cannabis and its derivatives on anthropometric measures in obese adults.
The study involved 27 selected trials comprising 4,394 participants from various countries, including France, the UK, the US, Canada, Argentina and others.
As first reported by News Medical Life Sciences, cannabis derivatives, such as rimonabant, hemp oil, cannabidiol, caryophyllene, and tetrahydrocannabinol (THC), demonstrated promise in reducing body weight, body mass index (BMI), and waist circumference.
Participants using these cannabis products experienced an average weight reduction of 1.87 kg and a 2 cm decrease in waist circumference. However, the impact on BMI was marginal, and body fat increased by 0.58%. Notably, longer follow-up periods were associated with more significant reductions in BMI.
Sub-group analyses highlighted that participants using cannabinoid receptor 2 (CB2) antagonist/agonist achieved a greater weight reduction, while those using cannabinoid receptor 1 (CB1) antagonist/agonist saw a notable decrease in both BMI and waist circumference. The CB1 receptor is known to be involved in appetite regulation and energy balance, while CB2 receptors play a role in immune and metabolic functions.
It's worth noting that cannabis oil resulted in only a minimal reduction in body fat, while other products, especially CB1 antagonist/agonist, increased body fat.
The study suggested that "cannabis and subproducts could be considered adjuncts in obesity treatment by helping to reduce relevant anthropometric measurements."
Read Next: Marijuana And Your Metabolism: Is Weed The New Player In The Weight Loss World?
Image by Diana Polekhina On Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!